semaglutide tablets novo nordisk Wegovy for Weight Management Here's Novo Nordisk's First Oral

GLP-1 RA T2D market (~4.5 yrs post-launch)

Since it is currently the only approved form of oral GLP-1, well compare it to the injectable version of semaglutide

According to the findings, 36% of current GLP-1 users report currently microdosing, 32% of users say they used to microdose in the past, but have stopped, and 32% say they have never microdosed

The microscopic needles gently penetrate the skin's surface, enhancing the absorption of potent actives and promoting cell-to-cell communication

That is why most patients purchase semaglutide without insurance or use compounded semaglutide for weight loss when personalized formulations are needed

GLP-1 receptor activation enhances insulin secretion in response to elevated blood glucose, suppresses glucagon release, slows gastric emptying, and reduces appetite through central nervous system pathways